September 1, 1997American Journal of Obstetrics and GynecologyOpen Access

Modern oral contraceptives and cardiovascular disease

View Full Paper

Ask AI

Bookmark

Why the study?

Do modern combined oral contraceptives improve cardiovascular safety compared to earlier formulations in young women?

Population

Young women

Comparison

Combined oral contraceptives containing second… vs Earlier formulations of oral contraceptives

Design

Review

Authors

LRLynn RosenbergBoston University JPJulie R. PalmerBoston University MSMarti I. Sands

Discussion

Member takes

Implication

Supports preferential prescribing of modern formulations; leaves open need for prospective trials to confirm net cardiovascular benefit.

Structured PICO

Do modern combined oral contraceptives improve cardiovascular safety compared to earlier formulations in young women?

Population

Young women

Intervention

Combined oral contraceptives containing second- and third-generation progestogens (such as desogestrel or gestodene) and < 50 micrograms of estrogen

Comparator

Earlier formulations of oral contraceptives

Outcome

Cardiovascular safety (incidence of venous thromboembolism, myocardial infarction, and stroke)safety

Modern combined oral contraceptives with lower estrogen doses and newer progestogens offer a better cardiovascular safety profile than older formulations.

Limitations

Differences between users in underlying risk and likelihood of being diagnosed may have contributed to the observed differences in venous thromboembolism risk between second- and third-generation formulations
Findings regarding the specific risk of myocardial infarction with second- versus third-generation formulations require confirmation

Cite This Study

Rosenberg et al. (1997) studied this question.

synapsesocial.com/papers/6a7142fd5d37378ac1de6a95 https://doi.org/10.1016/s0002-9378(97)70168-6

Topics

Women and heart disease

View Full Paper

Ask AI

Bookmark